

1 **A high-affinity antibody against the CSP N-terminal domain lacks *Plasmodium falciparum***
2 **inhibitory activity**

3

4 **Authors:**

5 Elaine Thai^{1,2*}, Giulia Costa^{3*}, Anna Weyrich^{3*}, Rajagopal Murugan⁴, David Oyen⁵, Katherine
6 Prieto², Alexandre Bosch², Angelo Valleriani^{3,6}, Nicholas C. Wu⁵, Tossapol Pholcharee⁵, Stephen
7 W. Scally¹, Ian A. Wilson^{5,7}, Hedda Wardemann^{4†}, Jean-Philippe Julien^{1,2,8†}, Elena A. Levashina^{3†}

8

9 **Affiliations:**

10 ¹Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON,
11 M5G 1X8, Canada

12 ²Department of Biochemistry, University of Toronto, ON, M5G 0A4, Canada

13 ³Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin 10117, Germany

14 ⁴B Cell Immunology, German Cancer Research Institute (DKFZ), Heidelberg 69120, Germany

15 ⁵Department of Integrative Structural and Computational Biology, The Scripps Research Institute,
16 La Jolla, CA, 92037, United States of America

17 ⁶Department of Theory and Biosystems, Max Planck Institute of Colloids and Interfaces, Potsdam
18 14476, Germany

19 ⁷The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037,
20 United States of America

21 ⁸Department of Immunology, University of Toronto, ON, M5G 0A4, Canada

22

23 *These authors contributed equally.

24 †To whom correspondence should be addressed:

25

26 Elena Levashina

27 Vector Biology Unit

28 Max Planck Institute for Infection Biology

29 Campus Charité Mitte

30 Charitéplatz 1

31 10117 Berlin, Germany

32 Tel: +49 30 28460 223

33 levashina@mpiib-berlin.mpg.de

34

35 Jean-Philippe Julien

36 The Hospital for Sick Children Research Institute

37 Peter Gilgan Centre for Research and Learning (PGCRL), Room 20-9703

38 686 Bay St. Toronto ON Canada M5G 0A4

39 Tel: 416-813-7654 ext.309424

40 jean-philippe.julien@sickkids.ca

41

42 Hedda Wardemann

43 B Cell Immunology (D130)

44 Deutsches Krebsforschungszentrum

45 Im Neuenheimer Feld 280

46 69120 Heidelberg, Germany

47 Tel: +49 6221 42 1270

48 h.wardemann@dkfz.de

49

50

51

52 **Abstract**

53 Malaria is a global health concern and research efforts are ongoing to develop a superior vaccine
54 to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the
55 protective humoral response against *Plasmodium falciparum* circumsporozoite protein (PfCSP).
56 In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody
57 response against the N-terminal domain of PfCSP (N-CSP) remains obscure. Here, we
58 characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal
59 antibody 5D5. The crystal structure at 1.85 Å resolution revealed that 5D5 binds an α -helical
60 epitope in N-CSP with high affinity through extensive shape and charge complementarity, and the
61 unusual utilization of an N-linked glycan. Nevertheless, functional studies indicated low 5D5
62 binding to live Pf sporozoites, and lack of sporozoite inhibition *in vitro* and in mosquitoes. Overall,
63 our data on low recognition and inhibition of sporozoites do not support the inclusion of the 5D5
64 epitope into the next generation of CSP-based vaccines.

65 **Summary Statement**

66 The *Plasmodium falciparum* sporozoite surface protein, PfCSP, is an attractive vaccine target, but
67 the antibody response against the CSP N-terminal domain has remained understudied. Here, to
68 guide immunogen design, Thai et al. provide insights into the binding motif and functional efficacy
69 of the N-terminal domain-specific monoclonal antibody, 5D5.

70 **Introduction**

71 Malaria is a vector-borne disease of global importance. In 2017, an estimated 219 million
72 cases were reported, resulting in 435,000 deaths (WHO, 2018). The majority of deaths are caused
73 by *Plasmodium falciparum* (Pf), making this parasite a central focus of research efforts for the
74 development of effective therapeutic interventions. Anti-infection vaccines target the sporozoite
75 stage of the Pf life cycle as parasites are transmitted to the human host by infected female
76 *Anopheles* mosquitos during a blood meal. It has been established four decades ago that mAbs
77 targeting the sporozoite surface circumsporozoite protein (CSP) are capable of neutralizing
78 *Plasmodium* infection (Potocnjak et al., 1980; Yoshida et al., 1980; Yoshida et al., 1981; Cochrane
79 et al., 1982). This year, the current leading anti-infection CSP-based vaccine against Pf malaria,
80 RTS,S/AS01, has begun pilot implementation in Ghana, Malawi and Kenya. Notwithstanding,
81 RTS,S/AS01 has shown to only provide rapidly waning protection in 50% of children and thus,
82 intense research efforts are underway towards designing a more efficacious and durable anti-CSP
83 vaccine (RTS,S Clinical Trials Partnership, 2015; Julien and Wardemann, 2019).

84 A molecular understanding of how the most potent monoclonal antibodies (mAbs)
85 recognize sites of vulnerability on the parasite can guide next-generation vaccine design. PfCSP is
86 composed of an N-terminal domain (N-CSP), a central repeat region comprising NANP motifs of
87 varied number that are interspersed with related NVDP motifs, and a C-terminal domain (C-CSP)
88 that comprises a linker region preceding an α -thrombospondin type-1 repeat (α TSR) domain (Fig.
89 1A). PfCSP is linked to the parasite membrane through a glycosylphosphatidylinositol anchor site.
90 Numerous studies have shown that mAbs specific for the NANP repeat region and the junction
91 immediately following N-CSP, which contains NANP motifs, NVDV motifs and the only copy of
92 an NPDP motif, can mediate protection in animal models (Potocnjak et al., 1980; Yoshida et al.,

93 1980; Foquet et al., 2014; Oyen et al., 2017; Triller et al., 2017; Kisalu et al., 2018; Tan et al.,
94 2018; Imkeller et al., 2018; Murugan et al., 2019). The few described mAbs to C-CSP were
95 functionally ineffective, probably, due to low accessibility of this domain on the sporozoite surface
96 (Sally et al., 2018). In contrast, the functional relevance of N-CSP mAbs remains elusive. To
97 date, no human mAb specific for this domain and only a handful of murine mAbs from
98 immunization studies with recombinant Pf N-CSP have been reported (Espinosa et al., 2015;
99 Herrera et al., 2015). These mAbs recognized N-CSP epitopes adjacent to Region I (RI; Fig. 1A),
100 a site with high conservation across *Plasmodium* species, suggesting that RI may be a good target
101 for cross-species vaccine development (Dame et al, 1984; Espinosa et al., 2015). Additionally,
102 proteolytic cleavage of RI was linked to efficient sporozoite invasion of host hepatocytes (Espinosa
103 et al., 2015; Coppi et al., 2005). Based on these observations, it has been proposed that adding N-
104 CSP, including the RI motif, into a PfCSP subunit vaccine may improve protective efficacy
105 compared to the current leading vaccine RTS,S/AS01, which lacks this domain. However, passive
106 transfer of the most potent RI-targeting mAb 5D5 protected mice from infection in only one of the
107 two tested transgenic rodent *P. berghei* (Pb) models that expressed a chimeric PbCSP with the Pf
108 N-CSP domain (Espinosa et al., 2015), and its impact on Pf has not been determined. Thus, crucial
109 information on how mAb 5D5 binds and inhibits Pf sporozoites is still missing.

110 To gain a molecular understanding of how the mAb 5D5 recognizes PfCSP and inhibits Pf
111 sporozoite infectivity, we solved the crystal structure of the 5D5 Fab in complex with a peptide
112 derived from N-CSP and conducted in-depth binding and functional experiments with Pf
113 sporozoites. We specifically quantified reactivity of mAb 5D5 to single live Pf sporozoites isolated
114 from the midgut and salivary glands of mosquitoes using imaging flow cytometry, and tested its
115 inhibitory potency against Pf sporozoites through *in vitro* traversal assays and *in vivo* passive mAb

116 transfer experiments in mosquitoes. Our work provides a detailed molecular and functional
117 understanding of mAb 5D5 recognition of its epitope, and highlights poor recognition of this N-
118 CSP epitope on the Pf sporozoite surface.


119

120 **Results and Discussion**

121 **mAb 5D5 binds an α -helical motif in N-CSP**

122 To understand the molecular basis for mAb 5D5 recognition of PfCSP, we solved the
123 crystal structure of the 5D5 Fab in complex with PfCSP₈₁₋₉₈ to 1.85 Å resolution (Supplementary
124 Table 1). We specifically selected PfCSP residues 81-98 for our studies to ensure inclusion of the
125 mAb 5D5 epitope, identified as Pf N-CSP residues 82-91 by yeast display epitope mapping (Fig.
126 1A and S1A) in agreement with previous reports (Espinosa et al., 2015), as well as conserved RI
127 residues KLLKQP in positions 93-97. Consistent with our yeast display experiments, we observed
128 strong electron density for N-CSP residues 81-92 (EDNEKLRKPKHK) in the crystal structure
129 (Fig. S1B). PfCSP residues 83-91 formed an α -helix when bound by 5D5 Fab (Fig. 1B), in line
130 with secondary structure predictions based on the primary sequence (Drozdetskiy et al., 2015).
131 Importantly, while structures of a variety of polypeptides derived from PfCSP (the junctional
132 region following N-CSP, the NANP repeat region, and the C-terminal α TSR domain) have been
133 solved in complex with a broad range of antibodies (Oyen et al., 2017; Imkeller et al., 2018; Scally
134 et al., 2018; Tan et al., 2018; Kisalu et al., 2018; Julien and Wardemann, 2019; Murugan et al.,
135 2019), our crystal structure of the 5D5 Fab in complex with PfCSP₈₁₋₉₈ provides the first insight
136 into the subdomain architecture of Pf N-CSP. However, further studies are needed to elucidate the
137 conformation of residues comprising RI, which were disordered and unresolved in our crystal
138 structure, as well as the overall structure of Pf N-CSP.

139



140

141 **Figure 1. Molecular delineation of the mAb 5D5 epitope in PfCSP.** (A, above) Schematic depicting the protein
 142 domain organization of PfCSP shown with the approximate location of Region I (RI) indicated by the black box and
 143 the junctional epitope represented by a dark red band. An approximate representation of PfCSP₈₁₋₉₈ is illustrated by
 144 the black bar (not shown to scale). (Below) Heatmap of mAb 5D5 binding affinity for N-CSP single point mutant
 145 library. N-CSP residues included in PfCSP₈₁₋₉₈ are indicated by the bracket at the bottom. The relative binding affinity
 146 is indicated by a diverging colour scale from red to blue, where red indicates a similar affinity while blue indicates
 147 decreased affinity. The X-axis denotes the N-CSP residue position and the Y-axis specifies the introduced single point
 148 mutations. Residues corresponding to the WT sequence are indicated by the gray dots. (B) Crystal structure showing
 149 the 5D5 Fab variable regions (heavy chain shown in red and kappa light chain shown in blue) bound to PfCSP N-
 150 terminal residues 81-92 (yellow), which are recognized in an α-helical conformation. The N-linked glycan on H.Asn98
 151 of 5D5 Fab is represented as sticks. (C) mAb 5D5 CDRs contacting PfCSP. HCDRs 1, 2, and 3 (salmon, raspberry
 152 and firebrick red, respectively), and KCDRs 1 and 3 (light teal and deep teal, respectively) contribute to 5D5 Fab
 153 recognition, whereas KCDR2 (teal) does not. (D) Electrostatic surface potential of mAb 5D5 bound to PfCSP₈₁₋₉₈.
 154 mAb 5D5 displays extensive shape and charge complementarity to PfCSP. Electrostatic calculations were performed
 155 using APBS (Baker et al., 2001) and rendered in Pymol (The PyMOL Molecular Graphics System, Version 2.0
 156 Schrödinger, LLC); scale: -5 kT/e (red) to +5 kT/e (blue). (E) H-bonds (shown as black dashed lines) formed between
 157 mAb 5D5 HCDR residues and negatively charged PfCSP residues. Water molecules are shown as red spheres.

158 mAb 5D5 contacts PfCSP with all complementarity-determining regions (CDRs) except
159 kappa light chain CDR 2 (KCDR2; Fig. 1C). The heavy chain CDRs (HCDRs) form the majority
160 of interactions with 498 Å² buried surface area (BSA) compared to 160 Å² BSA for the kappa light
161 chain. Furthermore, the mAb 5D5 CDRs possess extensive shape and electrostatic
162 complementarity to this highly charged N-CSP epitope (Fig. 1D). An electropositive pocket
163 formed by HCDR2 contacts PfCSP residues D82 and E84 via H-bonds with Ser54^{O γ} , Asn56^{N δ 2},
164 and Tyr58^{OH}, and water-mediated H-bonds with Arg53^N and Ser54^{O γ} (Fig. 1E). Additionally, an
165 electronegative pocket formed by HCDR2, HCDR3, KCDR1, and KCDR3 contacts PfCSP
166 electropositive residues R87, K90 and H91 via several H-bonds and salt bridges (Fig. 2A). The
167 significance of this shape and charge complementarity for high affinity binding was observed in
168 our yeast display experiments, as mutations maintaining both side chain length and electrostatic
169 properties, such as K90R, were more likely to sustain high affinity binding than those that did not
170 (K90E, K90D; Fig. 1A).


171 Consistent with prediction from the primary mAb 5D5 sequence, we observed electron
172 density for two GlcNAc and one α 1-6Fuc moieties indicative of N-linked glycosylation at Asn98
173 of HCDR3 (Fig. 2A and S1C). Importantly, the first N-linked GlcNAc moiety contacts the
174 aliphatic portion of K90 of PfCSP₈₁₋₉₈, conferring 48 Å² of BSA, while the other sugars did not
175 interact with the peptide. In this way, the paratope glycan contributes to mAb 5D5 occlusion of
176 PfCSP residue K90. Interestingly, K90 is one of four lysine residues (including K85, K88, and
177 K92) directly upstream of RI that have previously been proposed to be important for binding
178 heparan sulfate proteoglycans on the surface of hepatocytes to initialize liver invasion (Zhao et al.,
179 2016). Notably, the α -helical conformation adopted by N-CSP residues 83-91 upon mAb 5D5
180 binding positions the remaining three lysine residues, K85, K88 and K92, on the same exposed

181 face of the helix (Fig. S1B). Thus, our molecular description of PfCSP recognition by mAb 5D5
182 demonstrates optimal antibody-antigen characteristics associated with high affinity binding to a
183 putative functional site on Pf sporozoites.

184

185 **mAb 5D5 paratope glycosylation is critical for high affinity recognition of recombinant** 186 **PfCSP**

187 To determine whether the N-linked glycan on H.Asn98 affects mAb 5D5 binding, we
188 generated four different forms of the mAb 5D5 glycan and measured their binding kinetics to full-
189 length PfCSP using biolayer interferometry (BLI; Fig. 2B-F). Specifically, we generated four 5D5
190 Fab variants with either: 1) a complex glycan, as in the crystal structure (by expression in HEK
191 293F cells; 293F); 2) a high mannose glycan (by expression in HEK 293S (GnT I^{-/-}) cells; 293S
192 (GnT I^{-/-})); 3) a single GlcNAc moiety (by expression in HEK 293S (GnT I^{-/-}) cells followed by
193 Endo H treatment; Endo H); or 4) an H.N98Q mutation removing the N-linked glycosylation site
194 altogether (5D5Δg). The 293F, 293S (GnT I^{-/-}) and Endo H-treated 5D5 Fabs bound with high
195 affinity to full-length PfCSP with K_D's of 39.7 ± 8.2 nM, 46.6 ± 4.7 nM and 85.8 ± 8.8 nM,
196 respectively (Fig. 2C-E). In contrast, the 5D5Δg mutant Fab bound PfCSP with weaker affinity
197 (K_D of 453 ± 110 nM) due to an 11-fold faster off-rate compared to HEK 293F-expressed 5D5 Fab
198 (Fig. 2B and F), while the on-rates of all glycoform Fabs remained within the same order of
199 magnitude. Together with the crystal structure, these results underline the importance of the
200 H.Asn98-linked GlcNAc moiety for high affinity mAb 5D5 binding to recombinant PfCSP, and
201 highlight a rare occurrence for such a post-translational modification to participate in the antibody-
202 antigen interaction and improve the kinetics of antigen binding.



203


204 **Figure 2. 5D5 paratope glycosylation mediates high affinity binding.** (A) Interactions formed by mAb 5D5
 205 H.AsN98-linked GlcNAc moiety and surrounding CDR residues with PfCSP. H-bonds are shown as black dashed
 206 lines, and salt bridges are shown as blue dashed lines. (B-F) Binding kinetics of twofold dilutions of (C) 293F, (D)
 207 293S (GnT I^{-/-}), (E) Endo H and (F) 5D5Δg Fab glycoform variants to full length PfCSP. (B) Mean k_{on} and k_{off} rates
 208 of the 5D5 Fab glycoform variants binding to full length PfCSP are plotted on the left and right y-axis, respectively.
 209 Mean k_{on} rates are shown as red circles, and mean k_{off} rates as blue triangles. (C-F) Representative sensorgrams are
 210 shown in black and 1:1 model best fits in red. Mean K_D values are as listed. K_D values, and k_{on} and k_{off} rates were
 211 determined by FortéBio's Data Analysis software 9.0. Standard error values are reported as the standard deviation.
 212 Data are representative of three independent measurements. Corresponding glycan structures are shown using symbols
 213 adhering to the Symbol Nomenclature for Glycans (Varki et al., 2015).

214

215 **mAb 5D5 does not efficiently bind or inhibit salivary gland Pf sporozoites**

216 The role of the N-linked glycan on H.AsN98 in the binding of 5D5 IgG to freshly isolated
 217 salivary gland Pf sporozoites was quantified by imaging flow cytometry. As these preparations

218 contained both live and dead sporozoites, we focused our analyses on live sporozoites that were
 219 negative for propidium iodide staining (Fig. S2). As positive and negative controls, we used human
 220 mAbs targeting the PfCSP central repeat (1210; Imkeller et al., 2018) and C-CSP (1710; Scally et
 221 al., 2018), respectively. In line with previous reports, mAb 1710 failed to recognize mature Pf
 222 sporozoites isolated from mosquito salivary glands, whereas mAb 1210 strongly bound these
 223 sporozoites (Fig. 3A-D). We detected a two-fold decrease in mean fluorescence intensity (MFI)
 224 between mAbs 1210- and 5D5- or 5D5Δg-bound sporozoites (Fig. 3C). The observed differences
 225 can be explained by the frequencies of the targeted epitopes on the sporozoite surface. Indeed,
 226 mAb 1210 likely binds repeated NANP motifs within the central region whereas mAbs 5D5 and
 227 5D5Δg can only react with a single N-CSP motif. In contrast to previous reports, we found that
 228 mAbs 5D5 did not bind the majority of sporozoites (Fig. 3B and D). Mutation of the glycosylation
 229 site further decreased the proportion of 5D5Δg-bound sporozoites from 27 to 13% (Fig. 3D). These
 230 results demonstrate the importance of mAb 5D5 paratope glycosylation for PfCSP binding on the
 231 sporozoite surface. However, they also reveal low levels of overall reactivity of this antibody to
 232 live salivary gland Pf sporozoites.



233

234 **Figure 3. mAb 5D5 binding to salivary gland sporozoites and traversal inhibition activity.** (A-D) Imaging flow
235 cytometry of live salivary gland sporozoites isolated from mosquito thorax after incubation with human mAb 1710 or
236 1210 (negative and positive controls, respectively), or mAb 5D5 or 5D5Δg. (A) Representative images of sporozoites
237 in brightfield (BF, left panels) and mAb-bound fluorescent sporozoites (right panels). Scale bars - 5 μm. Total number
238 of sporozoites analysed per condition is indicated in parentheses (N=3). (B) Comparative density plots of a
239 representative experiment showing the fluorescence intensities of three arbitrarily-designated groups of mAb-bound
240 sporozoites (neg – negative, + – low intensity, ++ – high intensity). (C) Mean fluorescence intensities (MFI) of the
241 mAb-positive sporozoites. (D) Quantification of mAb-positive sporozoites (%). (C-D) Colors show results of three
242 independent experiments. (E) Results of mAb inhibition of sporozoites in *in vitro* traversal assay tested at 100 μg/mL
243 mAb concentration (N=3). Statistically significant differences ($p < 0.05$) between the groups are indicated by different
244 letters (z-test (C and D); paired Friedman test followed by Dunn's *post-hoc* test (E)).
245


246 We next evaluated how the low sporozoite binding observed for mAb 5D5 translated into
247 inhibitory potency against Pf sporozoites in a hepatocyte traversal assay. In line with the mAb
248 binding efficiencies, only mAb 1210 completely blocked sporozoite traversal of hepatocytes,
249 whereas mAb 5D5 was as inefficient at inhibiting traversal as negative control mAb 1710,
250 regardless of the presence of the paratope glycan (Fig. 3E). Poor mAb 5D5 binding to sporozoites
251 and lack of traversal inhibition precluded further functional testing of mAb 5D5 in Pf infections in
252 a sophisticated humanized mouse model. We conclude that, in spite of high affinity interaction
253 with the N-CSP epitope in recombinant PfCSP, the overall low levels of mAb 5D5 binding to live
254 Pf sporozoites preclude efficient inhibition of parasite traversal.

255

256 **mAb 5D5 does not inhibit *in vivo* sporozoite development in mosquitoes**

257 As CSP is essential for sporozoite development in mosquitoes (Menard et al., 1997), we
258 extended our antibody binding and functional examination to immature Pf sporozoites isolated
259 from oocysts in the mosquito midgut (Fig. 4A). Similar to our observations with mature
260 sporozoites, mAb 5D5 exhibited low binding efficiency to immature sporozoites, as measured by
261 MFI and percentage of mAb-positive sporozoites determined using imaging flow cytometry (Fig.

262 4B-C). Also consistent with our findings with salivary gland sporozoites, paratope glycosylation
 263 increased the proportion of mAb 5D5-bound midgut sporozoites by two-fold (Fig. 4D).



264

265 **Figure 4. mAb 5D5 binding to midgut sporozoites and inhibition of sporogonic development within mosquitoes.**

266 (A-D) Imaging flow cytometry of live midgut sporozoites isolated from oocysts after incubation with human mAb
 267 1710 or 1210 (negative and positive controls, respectively), or mAb 5D5 or 5D5Δg. (A) Representative images of
 268 sporozoites in brightfield (BF, left panels) and mAb-bound fluorescent sporozoites (right panels). Scale bars - 5 μm.
 269 Total number of sporozoites analysed per condition is indicated in parentheses (N=3). (B) Comparative density plots
 270 of a representative experiment showing the fluorescence intensities of three arbitrarily-designated groups of mAb-
 271 bound sporozoites (neg – negative, + – low intensity, ++ – high intensity). (C) Mean fluorescence intensities (MFI) of
 272 the mAb-positive sporozoites. (D) Quantification of mAb-positive sporozoites (%). (C-D) Colors show results of three
 273 independent experiments. (E) Schematic representation of passive single-chain Fab (scFab) transfer by mosquito
 274 injection. (F) Results of scFab transfer experiments expressed relative to control PBS-injected mosquitoes (N=6, total
 275 mosquito numbers analyzed are indicated below in parentheses). The box plots show the upper and lower quantiles
 276 and the median of the distribution. Each dot represents normalized sporozoite loads in one experiment. Statistically
 277 significant differences ($p < 0.05$) between the groups are indicated by different letters (z-test (C and D); maximum
 278 likelihood estimation (MLE)(F)).

279

280 To evaluate the inhibitory activity of mAb 5D5 against Pf sporozoites in their natural
281 environment *in vivo*, we developed a passive mAb transfer assay for mosquitoes that examined
282 sporozoite maturation and salivary gland invasion. Mosquitoes were injected with recombinant
283 single-chain Fabs (scFabs) two days before Pf infection, and sporozoite loads in dissected salivary
284 glands were quantified two weeks later (Fig. 4E). Injection of scFab1210 significantly reduced the
285 number of mature sporozoites in the salivary glands. In contrast, transfer of scFab1710 or
286 scFab5D5 did not affect sporozoite development and invasion (Fig. 4F). Taken together, these
287 results demonstrate that mAb 5D5 fails to efficiently recognize its epitope on the surface of Pf
288 parasites, and lacks inhibitory potency against sporozoites in both the vector and the host.

289

290 **Concluding Remarks**

291 In this report, we demonstrate that despite high-affinity binding to recombinant PfCSP,
292 mAb 5D5 does not recognize the majority of live Pf sporozoites, indicating that its epitope is not
293 readily accessible or present on the sporozoite surface. Consequently, as shown in the current
294 study, mAb 5D5 is unable to block Pf sporozoite development in the mosquito or inhibit sporozoite
295 traversal of hepatocytes. The lack of potent human N-CSP-specific mAbs in multiple screens based
296 on full-length recombinant PfCSP baits or unbiased antigen-agnostic approaches (Fig. S3; Triller
297 et al., 2017; Murugan et al., 2018; Tan et al., 2018; Kisalu et al., 2018; Julien and Wardemann,
298 2019) is in line with these observations. Overall, to date, there is little evidence to support N-CSP
299 as a source of potent or protective epitopes to block Pf infection. Therefore, the repeating motifs
300 in the central domain and N-terminal junction remain the most promising PfCSP regions for anti-
301 infective vaccine design to elicit protective mAbs.

302 **Materials and Methods**

303 **Mutant N-CSP yeast display library construction and transformation**

304 Epitope mapping using phage display was adapted from a previously published method
305 (Van Blarcom et al., 2015). Construction of the mutant library required generation of a linearized
306 vector and a library of mutant N-CSP inserts. The mutant insert library was generated by two
307 rounds of PCR using primers that carried the randomized codon “NNK” (Tables S2 and S3), and
308 mixing the products (Amplicons 1 to 9) at an equal molar ratio. The vector was generated by
309 overlapping PCR using vector-F/R primers (Table S2). All PCR products were amplified using
310 KOD DNA polymerase (EMD Millipore) and purified by gel extraction (Clontech Libraries).

311 The EBY100 yeast strain was purchased from ATCC. The yeast vector was generated by
312 modification of the commercially available pCTcon2 vector (Addgene; Chao et al., 2006). The
313 mutant N-CSP insert was cloned with N-terminal V5 and C-terminal HA epitope tags. The Aga2p
314 yeast protein gene was inserted downstream of the HA epitope tag to allow for yeast surface
315 display of the N-CSP (plasmid pCTcon2-rsCSP-V5-HA-Aga2p). Yeast transformation was
316 performed as described previously (Benatuil et al., 2010). In summary, 4 µg of the linearized yeast
317 expression vector and 8 µg of the N-CSP mutant library insert were used for transformation.
318 Transformants were plated on SDCAA plates and incubated at 30°C for 2 days. Over 10⁸ colonies
319 were collected, resuspended in YPD media with 15% glycerol, and stored at -80°C until use.

320 **5D5 Fab production and purification**

321 mAb 5D5 V_L and V_H regions were individually cloned into pcDNA3.4-TOPO expression
322 vectors immediately upstream of human Igκ and Igγ1-C_H1 domains, respectively. The resulting
323 5D5 Fab light and heavy chain vectors were co-transfected into either HEK293F or HEK293S
324 (GnT I^{-/-}) cells for transient expression, and purified via KappaSelect affinity chromatography (GE

325 Healthcare), cation exchange chromatography (MonoS, GE Healthcare), and size exclusion
326 chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare). For binding studies, 5D5
327 Fab expressed in HEK293S (GnT I^{-/-}) cells was digested with Endoglycosidase H, followed by an
328 additional size exclusion chromatography step (Superdex 200 Increase 10/300 GL, GE
329 Healthcare). Lastly, the 5D5Δg Fab was produced by site-directed mutagenesis of the mAb 5D5
330 V_H region using Accuprime Pfx Supermix (Thermo Fisher Scientific). 5D5Δg Fab was expressed
331 in HEK293F cells and purified by chromatography as described above.

332 **IgG production and purification**

333 For yeast display experiments, mAb 5D5 was produced in ExpiCHO cells as a mouse IgG1
334 with AVI tag for biotinylation. The IgG was then purified using protein G affinity chromatography
335 (HiTrap Protein G HP, GE Healthcare) and size-exclusion chromatography (Superdex 200, GE
336 Healthcare). Biotinylation was performed as previously described (Ekiert et al., 2011).

337 For production of 5D5 and 5D5Δg IgGs for non-yeast display experiments, site-directed
338 mutagenesis was performed using In-Fusion (Takara Bio) on the pcDNA3.4-TOPO vectors
339 encoding the 5D5 Fab heavy chain and 5D5Δg Fab heavy chain sequences to substitute two stop
340 codons with two residues (DK), allowing for expression of the Igγ1-CH2 and Igγ1-CH3 domains.
341 5D5 IgG, 5D5Δg IgG, 1710 IgG (Scully et al., 2018), 1210 IgG (Imkeller et al., 2018), and IgGs
342 elicited by the PfSPZ-CVac Challenge (Mordmüller et al., 2017; Murugan et al., 2018) were
343 transiently expressed in HEK293F cells by co-transfection of paired Ig heavy and light chains, and
344 purified through protein A affinity chromatography (GE Healthcare), followed by size exclusion
345 chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).

346 **scFab production and purification**

347 scFab constructs were designed by cloning paired light and heavy chains, separated by a
348 72-residue linker, into a pcDNA3.4-TOPO expression vector. The resulting constructs were
349 transiently expressed in HEK293F cells, and purified by KappaSelect affinity chromatography
350 (GE Healthcare), followed by size exclusion chromatography (Superdex 200 Increase 10/300 GL,
351 GE Healthcare).

352 **Recombinant PfCSP production and purification**

353 A construct of full-length PfCSP isolated from strain NF54 (UniProt accession no. P19597,
354 residues 20-384) was designed with potential N-linked glycosylation sites mutated to glutamine
355 (Sally et al., 2018). The resulting construct was transiently transfected in HEK293F cells, and
356 purified by HisTrap FF affinity chromatography (GE Healthcare) and size exclusion
357 chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).

358 A construct encoding PfCSP residues 71-104 was cloned into a pETM-22 vector.
359 Competent BL21(DE3) *E. coli* cells were transformed with the resulting plasmid and cultured to
360 an optical density of approximately 0.6-0.8. Expression of PfCSP₇₁₋₁₀₄ was induced using 1 mM
361 isopropyl β-D-1-thiogalactopyranoside (IPTG). Approximately 4 h after induction, cells were
362 lysed by sonication, and purified through HisTrap affinity chromatography (GE Healthcare) and
363 size exclusion chromatography (Superdex 75 10/300 GL, GE Healthcare).

364 **Yeast display epitope mapping**

365 For each sorting round, ~10⁹ yeast cells from the frozen stock were cultured in 250 mL of
366 SDCAA media for 16 h at 27.5°C until an OD of 1.9 was reached. Cells were pelleted, resuspended
367 in 35 mL of SGR-CAA induction media and incubated for 30 h at 18°C until an OD of 1.4 was
368 reached. After harvesting approximately 8 mL of cell culture, the pellet was washed 3 times with
369 PBS and finally resuspended in 5 mL of PBS. Biotinylated 5D5 IgG was incubated with BB515-

370 streptavidin at a molar ratio of 1:2 for 20 min. The biotinylated 5D5 IgG-streptavidin BB515
371 complex and Anti-HA PE antibody were added to the 5 mL of resuspended yeast cells with a final
372 concentration of 20 nM for each stain, followed by overnight incubation at 4°C with head-to-head
373 rotation in the dark. Next, cells were washed twice with PBS, resuspended in 5 mL of PBS, and
374 sorted at the TSRI Flow Cytometry Core Facility. Two gates were applied for simultaneous sorting
375 (Fig. S1A): one where binding of 5D5 IgG was completely abrogated (PE only) and one where
376 binding was unaffected (PE and BB515). The second round of sorting saw significant enrichment
377 in either gate.

378 **Deep mutational scanning data analysis**

379 Sequencing data were obtained in FASTQ format and parsed using SeqIO module in
380 BioPython (Cock et al., 2009). After trimming the primers, a paired-end read was then filtered and
381 removed if the corresponding forward and reverse reads were not reverse-complemented. The
382 position of the randomized codon was then identified by the internal barcode. Each mutation was
383 called by comparing individual paired-end reads to the wild type (WT) reference sequence.
384 Frequency of mutation m in sample s was computed as:

$$385 \quad \text{Frequency}_{m,s} = \frac{\text{read count}_{m,s} + 1}{\text{total read count}_s}$$

386 Relative affinity of mutation m was computed as:

$$387 \quad \text{Relative affinity}_m = \log_{10} \left(\frac{\text{Frequency}_{m,\text{round 2 gate 1}}}{\text{Frequency}_{m,\text{round 2 gate 2}}} \div \frac{\text{Frequency}_{WT,\text{round 2 gate 1}}}{\text{Frequency}_{WT,\text{round 2 gate 2}}} \right)$$

388 The pseudo read count of 1 in the calculation of frequency was to prevent division by zero during
389 the calculation of relative affinity. Relative affinity of WT is 0.

390 Raw sequencing data have been submitted to the NIH Short Read Archive under accession
391 number: BioProject PRJNA578947. Custom python scripts for analyzing the deep mutational
392 scanning data have been deposited to https://github.com/wchnicholas/CSP_Nterm_yeast_display.

393 **Crystallization and structure determination**

394 Purified 5D5 Fab and CSP 81-98 peptide (GenScript) were mixed in a 1:5 molar ratio. The
395 5D5 Fab/CSP 81-98 complex was then mixed in a 1:1 ratio with 20% (w/v) PEG 3350, 0.2 M di-
396 ammonium citrate. Crystals appeared after ~20 h, and were cryoprotected in 15% (v/v) ethylene
397 glycol before being flash-frozen in liquid nitrogen. Data were collected at the 08ID-1 beamline at
398 the Canadian Light Source, processed and scaled using XDS (Kabsch, 2010). The structure was
399 determined by molecular replacement using Phaser (McCoy et al., 2007) and a Fab model from
400 our internal database as the search model. Refinement of the structure was performed using
401 phenix.refine (Adams et al., 2010) and iterations of refinement using Coot (Emsley et al., 2010).
402 The crystal structure has been deposited in the Protein Data Bank (PDB ID 6UUD).

403 **BLI binding studies**

404 BLI (Octet RED96, FortéBio) experiments were conducted to determine the binding
405 kinetics of the 5D5 Fab glycoform variants to recombinant PfCSP diluted to 10 µg/mL in kinetics
406 buffer (PBS, pH 7.4, 0.01% [w/v] BSA, 0.002% [v/v] Tween-20) was immobilized onto Ni-NTA
407 (NTA) biosensors (FortéBio). After a steady baseline was established, biosensors were dipped into
408 wells containing twofold dilutions of each 5D5 Fab glycoform variant in kinetics buffer. Tips were
409 then immersed back into kinetics buffer for measurement of the dissociation rate. Kinetics data
410 were analyzed using FortéBio's Data Analysis software 9.0, and curves were fitted to a 1:1 binding
411 model. Mean kinetic constants and corresponding standard deviation values are reported as the
412 result of three independent experiments for each 5D5 Fab glycoform variant.

413 BLI experiments were also done to determine the avidity of IgGs isolated from the PfSPZ-
414 CVac Challenge (Mordmüller et al., 2017) to full length recombinant PfCSP and N-CSP construct,
415 PfCSP₇₁₋₁₀₄. Unrelated malaria protein Pfs25 was used to block non-specific binding and 5D5 IgG
416 was used as a positive control. PfCSP₇₁₋₁₀₄, PfCSP or Pfs25 was diluted to 10 µg/mL in kinetics
417 buffer and immobilized onto Ni-NTA (NTA) biosensors (FortéBio). Once a stable baseline was
418 established, biosensors were dipped into wells, each containing a different IgG diluted to 500 nM
419 in kinetics buffer. Tips were subsequently dipped back into kinetics buffer to observe any
420 dissociation of IgG.

421 **Mosquito rearing, parasite infections and sporozoite isolations**

422 *Anopheles coluzzii* (Ngouso strain) mosquitoes were maintained at 29°C 70–80%
423 humidity 12/12 h day/night cycle. For *P. falciparum* infections, mosquitoes were fed for 15 min
424 on a membrane feeder with NF54 gametocytes cultured with O⁺ human red blood cells (Haema,
425 Berlin), and, thereafter, kept in a secured S3 laboratory according to the national regulations
426 (Landesamt für Gesundheit und Soziales, project number 297/13). The *P. falciparum* NF54 clone
427 used in this study originated from Prof. Sauerwein's laboratory (RUMC, Nijmegen) and was
428 authenticated for *Pfs47* genotype by PCR on genomic DNA. *P. falciparum* asexual cultures were
429 monthly tested for *Mycoplasma* contamination. Unfed mosquitoes were removed shortly after
430 infections. Blood fed mosquitoes were offered an additional uninfected blood meal eight days post
431 infection, maintained at 26°C for 12 and 14/15 days, and used for the midgut and salivary gland
432 dissections, respectively. The midgut or salivary gland sporozoites were isolated into HC-04
433 complete culture medium (MEM without L-glutamine (Gibco) supplemented with F-12 Nutrient
434 Mix with L-glutamine (Gibco) in 1:1 ratio, 15 mM HEPES, 1.5 g/L NaHCO₃, 2.5 mM additional
435 L-glutamine, 10% FCS) and kept on ice until further use.

436 **Imaging flow cytometry of sporozoites**

437 Isolated sporozoites were diluted in PBS/1% FCS to 3×10^6 /mL and incubated for 30 min
438 at 4°C with 1 µg/mL recombinant IgGs, washed ($16,000 \times g$, 4 min, 4°C) and incubated with Cy5-
439 conjugated anti-human IgG1 (0.4 µg/ml, DRFZ Core Facility, Berlin) for 30 min at 4°C. After
440 incubation with the secondary antibody, sporozoites were further incubated with propidium iodide
441 (20 µg/mL, Sigma Aldrich) for 5 min at room temperature as previously described (Costa et al.,
442 2018). Sporozoites were acquired after one wash in PBS using the ImageStreamX Mk II instrument
443 (Merck Millipore) with a 60X objective for 15-20 min per sample. The experiments were
444 performed in three replicates. To avoid a possible bias due to the variable pre-acquisition waiting
445 times on ice, the order of samples was swapped between the experimental replicates.
446 Quantification of propidium iodide staining was performed using the Intensity_MC_Ch04,
447 whereas mAb binding was quantified by Cy5-conjugated secondary antibody signal
448 Intensity_MC_Ch11. Single sporozoites were manually selected by brightfield images (Channel
449 9) and only live, propidium iodide-negative sporozoites were gated for mAbs binding efficiency
450 analysis (for gating strategy see Fig. S2). The analysis was performed with IDEAS 6.2 (Merck
451 Millipore). Raw data were exported as .txt files and represented in dot and density plots using
452 RStudio Version 1.1.453.

453 **Pf sporozoite hepatocyte traversal assay**

454 Pf traversal assays were performed as previously described (Triller et al., 2017). In brief,
455 the salivary gland sporozoites were isolated from mosquito thorax and treated with mAbs (100
456 µg/mL) for 30 min on ice. The sporozoite preparations were seeded on human hepatocytes (HC-
457 04; Sattabongkot et al., 2006) for 2 h at 37°C and 5% CO₂ in the presence of dextran-rhodamine
458 (0.5 mg/mL) (Molecular Probes). mAb-untreated Pf sporozoites were used to measure the

459 maximum traversal capacity. Cells incubated only with uninfected mosquito thoracic material
460 were used as a background control. Cells were washed and fixed with 1% (v/v) formaldehyde in
461 PBS. Dextran positivity was detected by FACS LSR II instrument (BD Biosciences). Data analysis
462 was performed by background subtraction and normalization to the maximum traversal capacity
463 of mAb-untreated Pf sporozoites using FlowJo v.10.0.8 (Tree Star).

464 **Passive transfer of scFabs into mosquitoes**

465 1-2-day-old female *A. coluzzii* mosquitoes were injected on ice with 100 ng (285 μ L) of scFab
466 diluted in PBS or with 285 μ L PBS as an injection control. Two days later, mosquitoes were
467 infected with *P. falciparum* NF54 following the protocol described above. Mosquito heads were
468 carefully pulled off 14 days later and the attached salivary glands were collected and washed with
469 PBS. Dissected salivary glands were pooled for each group, homogenized and the freshly isolated
470 sporozoites were counted using a Malassez hemocytometer. The average number of sporozoites
471 per mosquito was calculated for each group.

472 **Enzyme-linked immunosorbent assay**

473 Antigen ELISA detHigh binding 384 well polystyrene plates (Corning) were coated with
474 recombinantly expressed PfCSP₇₁₋₁₀₄ comprising N-CSP at 50 ng/well overnight at 4°C. 1% BSA
475 in PBS was used for blocking the wells at RT. Binding of mAbs to N-CSP was determined by
476 incubating the coated plates with serially diluted mAb at 4.00, 1.00, 0.25, 0.06 μ g/mL
477 concentrations. Bound mAb was detected using goat anti-human IgG-HRP (Jackson
478 ImmunoResearch) at 1:1,000 dilution in 1% BSA in PBS and One-step ABTS substrate (Roche).
479 Non-PfCSP reactive antibody, mGO53, was used as negative control (Wardemann et al., 2003).
480 Area under the curve (AUC) based on diluted antibody series was calculated using GraphPad
481 Prism 7.04 (GraphPad).

482 Statistical analysis

483 No samples were excluded from the analyses. Mosquitoes from the same batches were
484 randomly allocated to the experimental groups (age range: 1–2 days). The experimenters were not
485 blinded to the group allocation during the experiment and/or when assessing the outcome. Sample
486 sizes were chosen according to best practices in the field and previous experience (Costa et al.,
487 2018).

488 For Figures 3C and 4C, Mean Fluorescence Intensity (MFI) and standard error of the mean
489 (SEM) of the mAb-bound live sporozoites were first computed from the data. We then associated
490 an MFI and standard error to each treatment by computing the average MFI across the three
491 independent experiments and subsequently computing the standard deviation (STD) as $STD =$
492 $[(SEM_1^2 + SEM_2^2 + SEM_3^2)^{1/2}]/3$. The null hypothesis was that the MFIs of sporozoites bound by
493 the tested mAbs were not different. Due to the large sample sizes examined, a z-test was used to
494 compare the MFI of the three conditions, and the obtained p-values are summarized below with
495 significant p-values highlighted in green:

496

Fig. 3C	5D5	5D5Δg	Fig. 4C	5D5	5D5Δg
1210	<10 ⁻⁴	<10 ⁻⁴	1210	<10 ⁻⁴	<10 ⁻⁴
5D5	-	0.2	5D5	-	0.3
5D5Δg	-	-	5D5Δg	-	-

499

500 The combined *p*-values from the z-test were much smaller than the total sample size, which is
501 roughly 10⁴. *p*-values much smaller than the inverse of the population size were therefore rounded
502 up to 10⁻⁴.

503 For Figures 3D and 4D, sample sizes (*totI*) and proportion of mAb-bound sporozoites per
504 experiments (*posI*) for each independent experiment (N=3) are summarized below:

505
506
507
508
509
510
511
512

Fig. 3D	Exp 1		Exp 2		Exp 3	
	<i>totl</i>	<i>posl</i>	<i>totl</i>	<i>posl</i>	<i>totl</i>	<i>posl</i>
1710	806	0	589	1	1121	1
1210	266	223	447	401	138	112
5D5	545	176	487	82	1096	316
5D5Δg	592	95	665	69	653	81

Fig. 4D	Exp 1		Exp 2		Exp 3	
	<i>totl</i>	<i>posl</i>	<i>totl</i>	<i>posl</i>	<i>totl</i>	<i>posl</i>
1710	901	2	1987	1	1267	4
1210	222	219	681	675	837	831
5D5	262	67	728	229	1456	366
5D5Δg	471	72	738	97	1482	193

513 The null hypothesis was that the proportions of sporozoites bound by the tested mAbs were not
514 different. Normality was verified and a z-test was used to compare the fractions of mAb-bound
515 sporozoites. We first computed the fraction f of mAb-bound for each mosquito tissue, experiment
516 and treatment as $f_i = \text{pos}_i / \text{tot}_i$. The fraction f can be considered as the probability that a
517 sporozoite taken at random is bound by a certain mAb. The error associated to f is therefore given
518 by $s(f) = \sqrt{f(1-f)/N}$, where N is the sample size given in the column *totl*. Within each
519 experiment, we used a two-sided z-test to test the null hypothesis that the fractions f associated to
520 the tested mAbs were not different, resulting in six pairwise comparisons per experiment. The
521 resulting p -values from the three independent experiments were combined using Fisher method
522 and are summarized below with significant p -values highlighted in green:

523
524
525

Fig. 3D	1210	5D5	5D5Δg	Fig. 4D	1210	5D5	5D5Δg
1710	<10 ⁻⁴	<10 ⁻⁴	<10 ⁻⁴	1710	<10 ⁻⁴	<10 ⁻⁴	<10 ⁻⁴
1210	-	<10 ⁻⁴	<10 ⁻⁴	1210	-	<10 ⁻⁴	<10 ⁻⁴
5D5		-	<10 ⁻⁴	5D5		-	<10 ⁻⁴

526

527 For both Figures 3D and 4D, the fractions f organized from strong to weak are as follows: 1210,
528 5D5, 5D5Δg, 1710. The combined p -values computed with the Fisher method are much smaller
529 than the total sample size, which is roughly 10⁴. The reported p -values are therefore the inverse of
530 the total sample size.

562
563
564
565
566
567
568

	PBS	5D5	1710	1210		PBS	5D5	1710	1210	
	Exp					Exp				
	1	1.15	1.07	1.37	0.97	1	21	25	15	16
	2	0.33	0.14	0.36	0.42	2	27	18	27	28
	3	33.3	2.44	1.76	1.37	3	11	11	11	11
	4	0.43	0.22	0.32	0.52	4	17	22	20	19
	5	0.47	0.38	0.56	0.36	5	19	16	16	18
	6	0.43	0.26	0.39	0.27	6	16	20	20	17
	Shape parameter k (MLE)					Numbers of dissected mosquitoes used for oocyst count to perform MLE estimates				

569 We then assumed that the number of sporozoites was linearly proportional to the number of oocysts
570 (Vaughan et al., 1992; Stone et al., 2013; Miura et al., 2019). This allowed us to replace M (as
571 derived from oocysts distribution) in the negative binomial with the average sporozoite number as
572 given above. We used the MLE estimate of the shape parameter k and simulated 10,000
573 independent samples of mosquitoes of size given above. Each simulated sample is thus statistically
574 identical to those provided by the experimental data.

575 Finally, for each two treatments and for each pair of simulated samples, we tested the null
576 hypothesis that there is no difference between the treatments by random sampling while keeping
577 sample sizes as in the experimental data. We thus created a distribution of the difference between
578 the average number of sporozoites in the two treatments to be compared under this null
579 hypothesis. The comparison of this distribution with the difference in sporozoite numbers as
580 given by the experimental data produces the p -value listed below. The combined p -value using
581 the Fisher method and true from false positives were discriminated using the Benjamini-
582 Hochberg (BH) and the Benjamini-Liu (BL) methods at a false discovery rate $Q = 10^{-3}$.

583

584

585

586

587

588

		exp1	exp2	exp3	exp4	exp5	exp6	Fisher	BH	BL	
	trmt1	trmt2								Q = 1e-3	
	PBS	5D5	0.99	0.25	0.35	0.30	0.84	0.20	0.54	False	False
	PBS	1710	0.91	0.14	0.99	0.19	0.21	0.53	0.45	False	False
	PBS	1210	2e-3	0.07	0.02	0.12	0.01	0.09	8e-6	True	True
	5D5	1710	0.13	0.34	0.99	0.39	0.06	0.81	0.29	False	False
	5D5	1210	1e-4	0.22	0.08	0.30	0.01	0.31	1e-4	True	True
	1710	1210	3e-4	0.36	1e-3	0.40	0.01	0.09	3e-6	True	True

Comparison between treatments across experiments, *p*-values and FDR analysis.

589

590 To check the consistency of this method, we simulated the sampled mosquito populations but

591 skipped the shuffling across the samples.

592

593 (Online) Supplemental Material

594 Supplemental materials include three tables and three figures. Supplemental tables: X-ray

595 crystallography data collection and refinement (Table S1), description of primers used to generate

596 mutant insert library for yeast display (Table S2), and PCR reactions and products for mutant insert

597 library construction (Table S3). Supplemental figures: Experimental details of fluorescence-

598 activated cell sorting of 5D5 IgG yeast display epitope mapping library and crystal structure

599 (Figure S1), gating strategy for imaging flow cytometry quantification of mAb binding to live Pf

600 sporozoites (Figure S2), and human mAbs against the PfCSP N-CSP identified from analysis of

601 the PfSPZ-CVac samples (Figure S3).

602

603 Author contributions

604 ET, GC, AW, RM, DO, SWS, IAW, HW, JPI, EAL, conceived and designed the research; ET,

605 GC, AW, RM, DO, NCW, KP, AB, NW, TP performed the research; ET, GC, AW, RM, DO,

606 AV, SWS, IAW, NCW, PP, HW, JPJ, EAL, analyzed data; ET, GC, AW, HW, JPJ, EAL wrote
607 the paper with input from all authors.

608 **Acknowledgements**

609 We thank C. Kreschel for her support in Pf sporozoite production and cell culture, as well as H.
610 Ahmed, L. Spohr, M. Andres and D. Eyemann (Vector Biology Unit, Max Planck Institute for
611 Infection Biology, Berlin) for mosquito rearing and infections. The following reagents were
612 obtained from BEI Resources, National Institute of Allergy and Infectious Diseases, National
613 Institutes of Health: HC-04, hepatocyte (human), MRA-975, contributed by Jetsumon
614 Sattabongkot Prachumsri. E.T. is currently supported by a CIHR Canada Graduate Scholarship
615 and N.C.W. by NIH K99 AI139445. S.W.S was supported by a Hospital for Sick Children Lap-
616 Chee Tsui Postdoctoral Fellowship and a Canadian Institutes of Health Research (CIHR)
617 fellowship. This work was undertaken, in part, thanks to funding from the Bill and Melinda Gates
618 Foundation (OPP1179906; J.-P.J, H.W. and E.A.L., and OPP1170236; I.A.W.), the CIFAR Azrieli
619 Global Scholar program (J.-P.J.) and the Canada Research Chairs program (950-231604; J.-P.J.).
620 X-ray diffraction experiments were performed using beamline 08ID-1 at the Canadian Light
621 Source, which is supported by the Canada Foundation for Innovation, Natural Sciences and
622 Engineering Research Council of Canada, the University of Saskatchewan, the Government of
623 Saskatchewan, Western Economic Diversification Canada, the National Research Council Canada,
624 and the Canadian Institutes of Health Research. The authors declare no competing financial
625 interests.
626

627 **References**

- 628 1. World Health Organization. 2018. World malaria report 2018.
629 <https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/> (accessed
630 June 6, 2019).
- 631 2. Potocnjak, P., N. Yoshida, R.S. Nussenzweig, and V. Nussenzweig. 1980. Monovalent
632 fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice
633 against malaria infection. *J. Exp. Med.* 151:1504–1513. doi:10.1084/jem.151.6.1504.
- 634 3. Yoshida, N., R.S. Nussenzweig, P. Potocnjak, V. Nussenzweig, M. Aikawa. 1980.
635 Hybridoma produces protective antibodies directed against the sporozoite stage of malaria
636 parasite. *Science.* 207:71–73. doi:10.1126/science.6985745.
- 637 4. Yoshida, N., P. Potocnjak, V. Nussenzweig, and R.S. Nussenzweig. 1981. Biosynthesis of
638 Pb44, the protective antigen of sporozoites of *Plasmodium berghei*. *J. Exp. Med.* 154:1225–
639 1236. doi:10.1084/jem.154.4.1225.
- 640 5. Cochrane, A.H., F. Santoro, V. Nussenzweig, R.W. Gwadz, and R.S. Nussenzweig. 1982.
641 Monoclonal antibodies identify the protective antigens of sporozoites of *Plasmodium*
642 *knowlesi*. *Proc. Natl. Acad. Sci. USA.* 79:5651–5655. doi:10.1073/pnas.79.18.5651.
- 643 6. RTS,S Clinical Trials Partnership. 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine
644 with or without a booster dose in infants and children in Africa: final results of a phase 3,
645 individually randomised, controlled trial. *Lancet.* 386:31–45. doi:10.1016/S0140-
646 6736(15)60721-8.
- 647 7. Julien, J.-P., and H. Wardemann. 2019. Antibodies against *Plasmodium falciparum* malaria
648 at the molecular level. *Nat. Rev. Immunol.* 19: 761-775. doi:10.1038/s41577-019-0209-5.
- 649 8. Foquet, L., C.C. Hermsen, G. Van Gemert, E. Van Braeckel, K.E. Weening, R. Sauerwein, P.

- 650 Meuleman, and G. Leroux-roels. 2014. Vaccine-induced monoclonal antibodies targeting
651 circumsporozoite protein prevent *Plasmodium falciparum* infection. *J. Clin. Invest.* 124:140–
652 144. doi:10.1172/JCI70349.
- 653 9. Oyen, D., J.L. Torres, U. Wille-Reece, C.F. Ockenhouse, D. Emerling, J. Glanville, W.
654 Volkmuth, Y. Flores-Garcia, F. Zavala, A.B. Ward, C.R. King, and I.A. Wilson. 2017.
655 Structural basis for antibody recognition of the NANP repeats in *Plasmodium falciparum*
656 circumsporozoite protein. *Proc Natl Acad Sci USA.* 114:E10438–E10445.
657 doi:10.1073/pnas.1715812114.
- 658 10. Triller, G., S.W. Scally, G. Costa, M. Pissarev, C. Kreschel, A. Bosch, E. Marois, B.K. Sack,
659 R. Murugan, A.M. Salman, C.J. Janse, S.M. Khan, S.H.I. Kappe, A.A. Adegnika, B.
660 Mordmüller, E.A. Levashina, J.P. Julien, and H. Wardemann. 2017. Natural parasite
661 exposure induces protective human anti-malarial antibodies. *Immunity.* 47:1197-1209.e10.
662 doi:10.1016/j.immuni.2017.11.007.
- 663 11. Kisalu, N.K., A.H. Idris, C. Weidle, Y. Flores-Garcia, B.J. Flynn, B.K. Sack, S. Murphy, A.
664 Schön, E. Freire, J.R. Francica, A.B. Miller, J. Gregory, S. March, H.X. Liao, B.F. Haynes,
665 K. Wiehe, A.M. Trama, K.O. Saunders, M.A. Gladden, A. Monroe, M. Bonsignori, M.
666 Kanekiyo, A.K. Wheatley, A.B. McDermott, S.K. Farney, G.Y. Chuang, B. Zhang, N. Kc, S.
667 Chakravarty, P.D. Kwong, P. Sinnis, S.N. Bhatia, S.H.I. Kappe, B.K.L. Sim, S.L. Hoffman,
668 F. Zavala, M. Pancera, and R.A. Seder. 2018. A human monoclonal antibody prevents
669 malaria infection by targeting a new site of vulnerability on the parasite. *Nat. Med.* 24:408–
670 416. doi:10.1038/nm.4512.
- 671 12. Tan, J., B.K. Sack, D. Oyen, I. Zenklusen, L. Piccoli, S. Barbieri, M. Foglierini, C.S. Fregni,
672 J. Marcandalli, S. Jongo, S. Abdulla, L. Perez, G. Corradin, L. Varani, F. Sallusto, B.K.L.

- 673 Sim, S.L. Hoffman, S.H.I. Kappe, C. Daubenberger, I.A. Wilson, and A. Lanzavecchia.
674 2018. A public antibody lineage that potently inhibits malaria infection through dual binding
675 to the circumsporozoite protein. *Nat. Med.* 24:401–407. doi:10.1038/nm.4513.
- 676 13. Imkeller, K., S. Scally, A. Bosch, G. Pidelaserra Martí, G. Costa, G. Triller, R. Murugan, P.
677 Kremsner, S. Hoffman, B. Mordmüller, E. Levashina, J. Julien, and H. Wardemann. 2018.
678 Antihomotypic affinity maturation improves human B cell responses against a repetitive
679 epitope. *Science.* 360:1358–1362. doi:10.1126/science.aar5304.
- 680 14. Murugan, R., S.W. Scally, G. Costa, G. Mustafa, E. Thai, T. Decker, A. Bosch, K. Prieto,
681 E.A. Levashina, J.-P. Julien, and H. Wardemann. 2019. Evolution of protective human
682 antibodies against *Plasmodium falciparum* circumsporozoite protein repeat motifs. *bioRxiv.*
683 798769. doi:10.1101/798769.
- 684 15. Scally, S.W., R. Murugan, A. Bosch, G. Triller, G. Costa, B. Mordmüller, P.G. Kremsner,
685 B.K.L. Sim, S.L. Hoffman, E.A. Levashina, H. Wardemann, and J.P. Julien. 2018. Rare
686 PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against
687 malaria infection. *J. Exp. Med.* 215:63–75. doi:10.1084/jem.20170869.
- 688 16. Espinosa, D.A., G.M. Gutierrez, M. Rojas-Lopez, A.R. Noe, L. Shi, S.W. Tse, P. Sinnis, and
689 F. Zavala. 2015. Proteolytic cleavage of the *Plasmodium falciparum* circumsporozoite
690 protein is a target of protective antibodies. *J. Infect. Dis.* 212:1111–1119.
691 doi:10.1093/infdis/jiv154.
- 692 17. Herrera, R., C. Anderson, K. Kumar, A. Molina-Cruz, V. Nguyen, M. Burkhardt, K. Reiter,
693 R. Shimp, R.F. Howard, P. Srinivasan, M.J. Nold, D. Ragheb, L. Shi, M. DeCotiis, J. Aebig,
694 L. Lambert, K.M. Rausch, O. Muratova, A. Jin, S.G. Reed, P. Sinnis, C. Barillas-Mury, P.E.
695 Duffy, N.J. MacDonald, and D.L. Naruma. 2015. Reversible conformational change in the

- 696 *Plasmodium falciparum* circumsporozoite protein masks its adhesion domains. *Infect.*
697 *Immun.* 83:3771–3780. doi:10.1128/IAI.02676-14.
- 698 18. Dame, J.B., J.L. Williams, T.F. McCutchan, J.L. Weber, R.A. Wirtz, W.T. Hockmeyer, W.L.
699 Maloy, J.D. Haynes, I. Schneider, D. Roberts, G.S. Sanders, E.P. Reddy, C.L. Diggs, and
700 L.H. Miller. 1984. Structure of the gene encoding the immunodominant surface antigen on
701 the sporozoite of the human malaria parasite *Plasmodium falciparum*. *Science.* 225:593–599.
702 doi:10.1126/science.os-1.14.154.
- 703 19. Coppi, A., C. Pinzon-Ortiz, C. Hutter, and P. Sinnis. 2005. The *Plasmodium*
704 circumsporozoite protein is proteolytically processed during cell invasion. *J. Exp. Med.*
705 201:27–33. doi:10.1084/jem.20040989.
- 706 20. Drozdetskiy, A., C. Cole, J. Procter, and G.J. Barton. 2015. JPred4: a protein secondary
707 structure prediction server. *Nucleic Acids Res.* 43:W389–W394. doi:10.1093/nar/gkv332.
- 708 21. Baker, N.A., D. Sept, S. Joseph, M.J. Holst, and J.A. McCammon. 2001. Electrostatics of
709 nanosystems: application to microtubules and the ribosome. *Proc Natl Acad Sci USA.*
710 98:10037–10041. doi:10.1073/pnas.181342398.
- 711 22. Zhao, J., P. Bhanot, J. Hu, and Q. Wang. 2016. A comprehensive analysis of *Plasmodium*
712 circumsporozoite protein binding to hepatocytes. *PLoS One.* 11:e0161607.
713 doi:10.1371/journal.pone.0161607.
- 714 23. Varki, A., R.D. Cummings, M. Aebi, N.H. Packer, P.H. Seeberger, J.D. Esko, P. Stanley, G.
715 Hart, A. Darvill, T. Kinoshita, J.J. Prestegard, R.L. Schnaar, H.H. Freeze, J.D. Marth, C.R.
716 Bertozzi, M.E. Etzler, M. Frank, J.F.G. Vliegthart, T. Lütteke, S. Perez, E. Bolton, P.
717 Rudd, J. Paulson, M. Kanehisa, P. Toukach, K.F. Aoki-Kinoshita, A. Dell, H. Narimatsu, W.
718 York, N. Taniguchi, and S. Kornfeld. 2015. Symbol nomenclature for graphical

- 719 representations of glycans. *Glycobiology*. 25:1323–1324. doi:10.1093/glycob/cwv091.
- 720 24. Menard, R., A.A. Sultan, C. Cortest, R. Ahszulert, M.R. van Dijk, C.J. Janse, A.P. Waters,
721 R.S. Nussenzweig, and V. Nussenzweig. 1997. Circumsporozoite protein is required for
722 development of malaria sporozoites in mosquitoes. *Nature*. 385:336–340.
723 doi:10.1038/385336a0.
- 724 25. Murugan, R., L. Buchauer, G. Triller, C. Kreschel, G. Costa, G. Pidelaserra Martí, K.
725 Imkeller, C.E. Busse, S. Chakravarty, B.K.L. Sim, S.L. Hoffman, E.A. Levashina, P.G.
726 Kremsner, B. Mordmüller, T. Höfer, and H. Wardemann. 2018. Clonal selection drives
727 protective memory B cell responses in controlled human malaria infection. *Sci. Immunol.*
728 3:eap8029. doi:10.1126/sciimmunol.aap8029.
- 729 26. Van Blarcom, T., A. Rossi, D. Foletti, P. Sundar, S. Pitts, C. Bee, J. Melton Witt, Z. Melton,
730 A. Hasa-Moreno, L. Shaughnessy, D. Telman, L. Zhao, W.L. Cheung, J. Berka, W. Zhai, P.
731 Strop, J. Chaparro-Riggers, D.L. Shelton, J. Pons, and A. Rajpal. 2015. Precise and efficient
732 antibody epitope determination through library design, yeast display and next-generation
733 sequencing. *J. Mol. Biol.* 427:1513–1534. doi:10.1016/j.jmb.2014.09.020.
- 734 27. Chao, G., W.L. Lau, B.J. Hackel, S.L. Sazinsky, S.M. Lippow, and K.D. Wittrup. 2006.
735 Isolating and engineering human antibodies using yeast surface display. *Nat. Protoc.* 1:755–
736 768. doi:10.1038/nprot.2006.94.
- 737 28. Benatuil, L., J.M. Perez, J. Belk, and C.M. Hsieh. 2010. An improved yeast transformation
738 method for the generation of very large human antibody libraries. *Protein Eng. Des. Sel.*
739 23:155–159. doi:10.1093/protein/gzq002.
- 740 29. Ekiert, D.C., R.H.E. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F.
741 Cox, H.J.W.M. Korse, B. Brandenburg, R. Vogels, J.P.J. Brakenhoff, R. Kompier, M.H.

- 742 Koldijk, L.A.H.M. Cornelissen, L.L.M. Poon, M. Peiris, W. Koudstaal, I.A. Wilson, and J.
743 Goudsmit. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses.
744 *Science*. 333:843–850. doi:10.1126/science.1204839.
- 745 30. Mordmüller, B., G. Surat, H. Lagler, S. Chakravarty, A.S. Ishizuka, A. Lalremruata, M.
746 Gmeiner, J.J. Campo, M. Esen, A.J. Ruben, J. Held, C.L. Calle, J.B. Mengue, T. Gebru, J.
747 Ibáñez, M. Sulyok, E.R. James, P.F. Billingsley, K. Natasha, A. Manoj, T. Murshedkar, A.
748 Gunasekera, A.G. Eappen, T. Li, R.E. Stafford, M. Li, P.L. Felgner, R.A. Seder, T.L. Richie,
749 B.K.L. Sim, S.L. Hoffman, and P.G. Kremsner. 2017. Sterile protection against human
750 malaria by chemoattenuated PfSPZ vaccine. *Nature*. 542:445–449. doi:10.1038/nature21060.
- 751 31. Cock, P.J.A., T. Antao, J.T. Chang, B.A. Chapman, C.J. Cox, A. Dalke, I. Friedberg, T.
752 Hamelryck, F. Kauff, B. Wilczynski, and M.J.L. De Hoon. 2009. Biopython: freely available
753 Python tools for computational molecular biology and bioinformatics. *Bioinformatics*.
754 25:1422–1423. doi:10.1093/bioinformatics/btp163.
- 755 32. Kabsch, W. 2010. XDS. *Acta Crystallogr. D Biol. Crystallogr.* 66:125–132. [https://doi.org](https://doi.org/10.1107/S0907444909047337)
756 [/10.1107/S0907444909047337](https://doi.org/10.1107/S0907444909047337)
- 757 33. McCoy, A.J., R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read.
758 2007. Phaser crystallographic software. *J. Appl. Cryst.* 40:658–674. [https://doi.org](https://doi.org/10.1107/S0021889807021206)
759 [/10.1107/S0021889807021206](https://doi.org/10.1107/S0021889807021206)
- 760 34. Adams, P.D., P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd,
761 L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, et al. 2010. PHE NIX: a comprehensive
762 Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol.*
763 *Crystallogr.* 66:213–221. [https://doi.org](https://doi.org/10.1107/S0907444909052925)
[/10.1107/S0907444909052925](https://doi.org/10.1107/S0907444909052925)

- 764 35. Emsley, P., B. Lohkamp, W.G. Scott, and K. Cowtan. 2010. Features and development of
765 Coot. *Acta Crystallogr. D Biol. Crystallogr.* 66:486–501. [https://doi.org/10.1107](https://doi.org/10.1107/S0907444910007493)
766 /S0907444910007493
- 767 36. Costa, G., M. Gildenhard, M. Eldering, R.L. Lindquist, A.E. Hauser, R. Sauerwein, C.
768 Goosmann, V. Brinkmann, P. Carrillo-Bustamante, and E.A. Levashina. 2018. Non-
769 competitive resource exploitation within mosquito shapes within-host malaria infectivity and
770 virulence. *Nat. Commun.* 9:1–11. doi:10.1038/s41467-018-05893-z.
- 771 37. Sattabongkot, J., N. Yimamnuaychoke, S. Leelaudomlipi, M. Rasameesoraj, R. Jenwithisuk,
772 R.E. Coleman, R. Udomsangpetch, L. Cui, and T.G. Brewer. 2006. Establishment of a human
773 hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the
774 malaria parasites *Plasmodium falciparum* and *P. vivax*. *Am. J. Trop. Med. Hyg.* 74:708–715.
775 doi:10.4269/ajtmh.2006.74.708.
- 776 38. Wardemann, H., S. Yurasov, A. Schaefer, J.W. Young, E. Meffre, and M.C. Nussenzweig.
777 2003. Predominant autoantibody production by early human B cell precursors. *Science*.
778 301:1374–1377. doi:10.1126/science.1086907.
- 779 39. Vaughan, J.A., B.H. Noden, and J.C. Beier. 1992. Population dynamics of *Plasmodium*
780 *falciparum* sporogony in laboratory-infected *Anopheles gambiae*. *J. Parasitol.* 78:716–724.
- 781 40. Stone, W.J.R., M. Eldering, G.-J. Van Gemert, K.H.W. Lanke, L. Grignard, M.G. Van De
782 Vegte-Bolmer, R. Siebelink-Stoter, W. Graumans, W.F.G. Roeffen, C.J. Drakeley, R. W.
783 Sauerwein, and T. Bousema. 2013. The relevance and applicability of oocyst prevalence as a
784 read-out for mosquito feeding assays. *Sci. Rep.* 3:1–8. doi:10.1038/srep03418.
- 785 41. Miura, K., B.J. Swihart, B. Deng, L. Zhou, T.P. Pham, A. Diouf, M.P. Fay, and C.A. Long.
786 2019. Strong concordance between percent inhibition in oocyst and sporozoite intensities in a

787 *Plasmodium falciparum* standard membrane-feeding assay. *Parasit Vectors*. 12: 206.

788 doi:10.1186/s13071-019-3470-3.